Advertisement
Advertisement

NTLA

NTLA logo

Intellia Therapeutics, Inc

13.54
USD
Sponsored
-1.21
-8.20%
Jun 05, 16:00 UTC -4
Closed
exchange

After-Market

13.41

-0.13
-0.97%

NTLA Earnings Reports

Positive Surprise Ratio

NTLA beat 23 of 41 last estimates.

56%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.27M
/
-$0.84
Implied change from Q1 26 (Revenue/ EPS)
-5.15%
/
+3.70%
Implied change from Q2 25 (Revenue/ EPS)
+0.19%
/
-14.29%

Intellia Therapeutics, Inc earnings per share and revenue

On May 11, 2026, NTLA reported earnings of -0.81 USD per share (EPS) for Q1 26, beating the estimate of -0.93 USD, resulting in a 13.10% surprise. Revenue reached 15.05 million, compared to an expected 15.09 million, with a -0.27% difference. The market reacted with a +2.34% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.84 USD, with revenue projected to reach 14.27 million USD, implying an increase of 3.70% EPS, and decrease of -5.15% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
FAQ
For Q1 2026, Intellia Therapeutics, Inc reported EPS of -$0.81, beating estimates by 13.1%, and revenue of $15.05M, -0.27% below expectations.
The stock price moved up 2.34%, changed from $14.09 before the earnings release to $14.42 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 13 analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.84 and revenue of $14.27M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement